Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation / 전남의대학술지
Chonnam Medical Journal
;
: 6-11, 2020.
Article
in English
| WPRIM
| ID: wpr-787280
ABSTRACT
Cancer remains a leading cause of death, despite multimodal treatment approaches. Even in patients with a healthy immune response, cancer cells can escape the immune system during tumorigenesis. Cancer cells incapacitate the normal cell-mediated immune system by expressing immune modulation ligands such as programmed death (PD) ligand 1, the B7 molecule, or secreting activators of immune modulators. Chimeric antigen receptor (CAR) T cells were originally designed to target cancer cells. Engineered approaches allow CAR T cells, which possess a simplified yet specific receptor, to be easily activated in limited situations. CAR T cell treatment is a derivative of the antigen-antibody reaction and can be applied to various diseases. In this review, the current successes of CAR T cells in cancer treatment and the therapeutic potential of CAR T cells are discussed.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
United Nations
/
Receptors, Antigen
/
T-Lymphocytes
/
Cause of Death
/
Combined Modality Therapy
/
Carcinogenesis
/
Cell- and Tissue-Based Therapy
/
Immune System
/
Ligands
/
Antigen-Antibody Reactions
Limits:
Humans
Language:
English
Journal:
Chonnam Medical Journal
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS